Gilteritinib – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 71 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Gilteritinib - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Gilteritinib is an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Gilteritinib is an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK, and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Gilteritinib is an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and infection. সহজ বাংলা: শ্বেত রক্তকণিকা।" data-rx-term="leukocyte" data-rx-definition="Leukocyte means white blood cell, which helps fight infection. সহজ বাংলা: শ্বেত রক্তকণিকা।">leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK, and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.

Gilteritinib is an orally available small molecule inhibitor of FMS-like tyrosine kinase 3 (FLT3) which is used as an antineoplastic agent in the treatment of acute myeloid leukemia with FLT3 mutations. Gilteritinib is associated with a moderate rate of serum aminotransferase elevations during therapy and is suspected to cause rare instances of clinically apparent acute liver injury.

Gilteritinib is a member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have an FLT3 gene mutation. It has a role as an apoptosis inducer, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, and an antineoplastic agent. It is an N-methyl piperazine, a member of piperidines, a secondary amino compound, a monomethoxybenzene, a member of pyrazines, a primary carboxamide, an aromatic amine, and a member of oxanes.

Gilteritinib Fumarate is the fumarate salt form of gilteritinib, an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and infection. সহজ বাংলা: শ্বেত রক্তকণিকা।" data-rx-term="leukocyte" data-rx-definition="Leukocyte means white blood cell, which helps fight infection. সহজ বাংলা: শ্বেত রক্তকণিকা।">leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK, and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.

Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group.[rx] It is a pyrazine carboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies.[rx] Gilteritinib was developed by Astellas Pharma and FDA-approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.[rx]

Mechanism of Action

Gilteritinib is a potent selective inhibitor of both of the mutations, internal tandem duplication (ITD) and tyrosine kinase domain (TKD), of the FLT3 receptor. On the same note, gilteritinib also inhibits AXL and ALK tyrosine kinases. FLT3 and AXL are molecules involved in the growth of cancer cells. The activity of gilteritinib permits inhibition of the phosphorylation of FLT3 and its downstream targets such as STAT5, ERK, and AKT. The interest in FLT3 transmembrane tyrosine kinases was raised when studies reported that approximately 30% of the patients with acute myeloid leukemia presented a mutationally activated isoform. As well, the mutation ITD is associated with poor patient outcomes while the mutation TKD produces a resistance mechanism to FLT3 tyrosine kinase inhibitors and the AXL tyrosine kinase tends to produce a resistance mechanism to chemotherapies.

In preclinical trials, gilteritinib demonstrate an IC50 for the wild-type receptor of 5 nM, 0.7-1.8 nM for ITD-mutated, and comparable inhibition to other therapies in the TKD-mutated. As well, data showed a gilteritinib-driven inhibition of the receptor tyrosine kinase AXL which is known to modulate the activity of FLT3 in acute myeloid leukemia. Another important result _in vivo_ was the localization in high levels in xenografted tumors which indicated high selectivity. In phase 1/2 clinical trials, gilteritinib was shown to present a composite complete response of 41%, an overall response rate of 52%, a median duration of response of 20 weeks with a median overall survival of 31 weeks. In phase III clinical trials, gilteritinib reported a complete remission or complete remission with partial hematologic recovery in 21% of the patients.

Indications

  • Gilteritinib is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia with an FLT3 mutation detected by an FDA-approved test. This indication was expanded for a companion diagnostic to include use with gilteritinib such as the LeukoStrat CDx FLT3 Mutation Assay. Acute myeloid leukemia is a cancer that impacts the blood and bone marrow with a rapid progression. This condition produces low numbers of normal blood cells and the requirement of a continuous need for transfusions.
  • Gilteritinib is an AXL receptor tyrosine kinase inhibitor used to treat relapsed or refractory acute myeloid leukemia.
  • Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation.
  • Gilteritinib is an orally available small molecule inhibitor of FMS-like tyrosine kinase 3 (FLT3) which is used as an antineoplastic agent in the treatment of acute myeloid leukemia with FLT3 mutations.
  • Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation.
  • For the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an FMS-like tyrosine kinase 3 (FLT3) mutation.

Acute myeloid leukemia is cancer that impacts the blood and bone marrow with a rapid progression. This condition produces low numbers of normal blood cells and the requirement of continuous need for transfusions

Use in Cancer

Gilteritinib fumarate is approved to treat:

Gilteritinib fumarate is also being studied in the treatment of other types of cancer.

Contraindications

  • Hypersensitivity to the active component or any of the ingredients
  • Safety and efficacy have not been established in patients younger than 18 years.
  • low amount of magnesium in the blood
  • low amount of potassium in the blood
  • prolonged QT interval on EKG
  • abnormal EKG with QT changes from birth
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • pancreatitis
  • a type of brain disorder called posterior reversible encephalopathy syndrome

Dosage

Strengths: 40 mg

Acute Myeloid Leukemia

  • 120 mg orally once a day until disease progression or unacceptable toxicity
  • The response may be delayed. In the absence of disease progression or unacceptable toxicity, patients should be treated for a minimum of 6 months to allow time for a clinical response.
  • Select patients for the treatment of AML with this drug based on the presence of FLT3 mutations in the blood or bone marrow.

Dose Adjustments

DOSAGE MODIFICATIONS FOR TOXICITY:
DIFFERENTIATION SYNDROME:

  • If differentiation syndrome is suspected, administer systemic corticosteroids and initiate hemodynamic monitoring until symptom resolution and for a minimum of 3 days.
  • Interrupt therapy if severe symptoms persist for more than 48 hours after initiation of corticosteroids.
  • Resume therapy when symptoms improve to Grade 2 or lower.

POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME:

  • Discontinue therapy.

QTc INTERVAL GREATER THAN 500 MSEC:

  • Interrupt therapy; resume therapy at 80 mg orally once a day when QTc interval returns to within 30 msec of baseline or less than or equal to 480 msec.

QTc INTERVAL INCREASED BY MORE THAN 30 MSEC ON ECG ON DAY 8 OF CYCLE 1:

  • Confirm with ECG on Day 9; if confirmed, consider dose reduction to 80 mg orally once a day.
  • Interrupt therapy until pancreatitis is resolved; resume therapy at 80 mg orally once a day.

OTHER GRADE 3 OR HIGHER TOXICITY CONSIDERED RELATED TO TREATMENT:

  • Interrupt therapy until toxicity resolves to Grade 1; resume therapy at 80 mg orally once a day.

Administration advice:

  • Do not break or crush tablets.
  • This drug may be taken with or without food.
  • Administer this drug at approximately the same time each day.
  • If a dose is missed or not taken at the usual time, administer it as soon as possible on the same day, and at least 12 hours prior to the next scheduled dose; return to normal schedule the following day.
  • Do not administer 2 doses within 12 hours.

Side Effects

The Most Common

  • joint or muscle pain
  • extreme tiredness
  • nausea
  • vomiting
  • diarrhea
  • mouth sores
  • change in the ability to taste food
  • pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache
  • loss of appetite
  • difficulty falling asleep or staying asleep
  • seizures; pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache; decreased alertness; confusion; or vision changes
  • fast, pounding, or irregular heartbeat; fainting; loss of consciousness; or seizures
  • ongoing pain that begins in the stomach area but may spread to the back that may occur with or without nausea and vomiting

More common

  • Bloody urine
  • blurred vision
  • chest pain or tightness
  • chills
  • confusion
  • cough
  • decreased frequency or amount of urine
  • dizziness
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fainting
  • fast or irregular heartbeat
  • fever
  • pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache
  • increased thirst
  • lightheadedness
  • loss of appetite
  • lower back or side pain
  • nausea
  • nervousness
  • pounding in the ears
  • rapid, shallow breathing
  • recurrent fainting
  • slow heartbeat
  • sneezing
  • sore throat
  • stomach pain
  • sweating
  • swelling of the face, fingers, or lower legs
  • trouble breathing
  • unusual tiredness or weakness
  • vomiting
  • weight gain

Rare

  • Anxiety
  • blue or pale skin
  • chest discomfort
  • chest pain, possibly moving to the left arm, neck, or shoulder
  • difficulty swallowing
  • the action of the mouth
  • trouble sleeping
  • stomach pain
  • painting
  • fever
  • fluid build-up around the lungs (e.g., chest pain, cough, hiccups, rapid breathing)
  • increased frequency or severity of infections (symptoms may include fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness)
  • inflammation of the mouth and lips
  • low magnesium levels in the blood (e.g., weakness, tremors, muscle cramps, seizures)
  • low potassium levels in the blood (e.g., weakness, fatigue, muscle cramps, irregular heartbeat)
  • pain, numbness, or weakness in the hands and feet
  • signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath)
  • signs of clotting problems (e.g., unusual nosebleeds, bruising, blood in urine, coughing blood, bleeding gums, cuts that don’t stop bleeding)
  • signs of heart problems (e.g., fast, irregular heartbeat or pulse; chest pain; sudden weight gain; difficulty breathing; leg swelling)
  • signs of kidney failure (e.g., decreased urine production, swelling, fatigue, abdominal pain)
  • signs of kidney problems (e.g., change in the amount or color of urine, increased urination at night, blood in the urine, swelling in the feet or legs)
  • symptoms of high blood sugar (e.g., frequent urination, increased thirst, excessive eating, unexplained weight loss, poor wound healing, infections, fruity breath odor)
  • swelling in the feet, ankles, hands
  •  vomiting, weakness
  • shortness of breath
  • fluid build-up around the heart (e.g., fever, fatigue, muscle aches, shortness of breath, nausea, vomiting, diarrhea, fast or pounding heartbeat, light-headedness)
  • signs of an allergic reaction (e.g., wheezing, tightness in chest, troubled breathing, shortness of breath, or cough)
  • signs of posterior reversible encephalopathy syndrome (e.g., headache, seizures, weakness, confusion, high blood pressure, vision changes, difficulty thinking clearly

Drug Interactions

Drug-Food Interactions

  • Avoid grapefruit products. Grapefruit inhibits CYP3A metabolism, which may increase the serum concentration of gilteritinib.
  • Avoid St. John’s Wort. This herb induces CYP3A4 and p-glycoprotein, which may reduce the serum concentration of gilteritinib.
  • Take it at the same time every day.
  • Take it with or without food.

Pregnancy and Lactation

US FDA pregnancy category Not Assigned

Pregnancy

This medication should not be used during pregnancy due to the risk that it may cause harm to the unborn baby. If you become pregnant while taking this medication, contact your doctor immediately.

Lactation

It is not known if gilteritinib passes into breast milk. If you are breast-feeding and are taking this medication, it may affect your baby. Women are advised to avoid breastfeeding while taking this medication and for 2 months after taking the last dose.

How should this medicine be used?

Gilteritinib comes as a tablet to take by mouth. It is usually taken once daily with or without food for at least 6 months. Take gilteritinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take gilteritinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the tablets whole with water; do not split, chew, or crush them.

Your doctor may adjust your dose or temporarily or permanently stop your treatment depending on how well the medication works for you and if you experience any side effects. Talk to your doctor about how you are feeling during your treatment. Continue to take gilteritinib even if you feel well. Do not stop taking gilteritinib without talking to your doctor.

What special precautions should I follow?

Before taking gilteritinib,

  • tell your doctor and pharmacist if you are allergic to gilteritinib, any other medications, or any of the ingredients in gilteritinib tablets. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: certain antifungals such as fluconazole (Diflucan), itraconazole (Onmel, Sporanox), and ketoconazole; clarithromycin (Biaxin, in PrevPac); escitalopram (Lexapro); fluoxetine (Prozac); certain medications for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) such as efavirenz (Sustiva, in Atripla), indinavir (Crixivan), nelfinavir (Viracept), nevirapine (Viramune), ritonavir (Norvir, in Kaletra), and saquinavir (Invirase); certain medications for seizures such as carbamazepine (Carbatrol, Epitol, Tegretol, others), phenobarbital, and phenytoin (Dilantin, Phenytek); nefazodone; pioglitazone (Actos); rifabutin (Mycobutin); rifampin (Rifadin, Rimactane, in Rifamate, in Rifater); and sertraline (Zoloft). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with gilteritinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
  • tell your doctor what herbal products you are taking, especially St. John’s wort.
  • tell your doctor if you have or have ever had a QT interval prolongation (an irregular heart rhythm that can lead to fainting, loss of consciousness, seizures, or sudden death); a slow, fast, or irregular heartbeat; or low levels of potassium or magnesium in your blood.
  • tell your doctor if you are pregnant, plan to become pregnant, or if you plan to father a child. You or your partner should not become pregnant while you are taking gilteritinib. If you are female, you will need to have a pregnancy test at least 7 days before you start treatment, and you should use birth control during your treatment and for 6 months after your final dose. If you are male, you and your partner should use birth control to prevent pregnancy during your treatment and for 4 months after your final dose. Talk to your doctor about birth control methods that you can use during your treatment. If you or your partner become pregnant while taking gilteritinib, call your doctor. Gilteritinib may harm the fetus.
  • tell your doctor if you are breastfeeding. You should not breastfeed during your treatment with gilteritinib and for 2 months after your final dose.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Gilteritinib – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action Gilteritinib is a potent selective inhibitor of both of the mutations, internal tandem duplication (ITD) and tyrosine kinase domain (TKD), of the FLT3 receptor. On the same note, gilteritinib also inhibits AXL and ALK tyrosine kinases. FLT3 and AXL are molecules involved in the growth of cancer cells. The activity of gilteritinib permits inhibition of the phosphorylation of FLT3 and its downstream targets such as STAT5, ERK, and AKT. The interest in FLT3 transmembrane tyrosine kinases was raised when studies reported that approximately 30% of the patients with acute myeloid leukemia presented a mutationally activated isoform. As well, the mutation ITD is associated with poor patient outcomes while the mutation TKD produces a resistance mechanism to FLT3 tyrosine kinase inhibitors and the AXL tyrosine kinase tends to produce a resistance mechanism to chemotherapies. In preclinical trials, gilteritinib demonstrate an IC50 for the wild-type receptor of 5 nM, 0.7-1.8 nM for ITD-mutated, and comparable inhibition to other therapies in the TKD-mutated. As well, data showed a gilteritinib-driven inhibition of the receptor tyrosine kinase AXL which is known to modulate the activity of FLT3 in acute myeloid leukemia. Another important result _in vivo_ was the localization in high levels in xenografted tumors which indicated high selectivity. In phase 1/2 clinical trials, gilteritinib was shown to present a composite complete response of 41%, an overall response rate of 52%, a median duration of response of 20 weeks with a median overall survival of 31 weeks. In phase III clinical trials, gilteritinib reported a complete remission or complete remission with partial hematologic recovery in 21% of the patients. Indications Gilteritinib is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia with an FLT3 mutation detected by an FDA-approved test. This indication was expanded for a companion diagnostic to include use with gilteritinib such as the LeukoStrat CDx FLT3 Mutation Assay. Acute myeloid leukemia is a cancer that impacts the blood and bone marrow with a rapid progression. This condition produces low numbers of normal blood cells and the requirement of a continuous need for transfusions. Gilteritinib is an AXL receptor tyrosine kinase inhibitor used to treat relapsed or refractory acute myeloid leukemia. Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation. Gilteritinib is an orally available small molecule inhibitor of FMS-like tyrosine kinase 3 (FLT3) which is used as an antineoplastic agent in the treatment of acute myeloid leukemia with FLT3 mutations. Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation. For the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an FMS-like tyrosine kinase 3 (FLT3) mutation. Acute myeloid leukemia is cancer that impacts the blood and bone marrow with a rapid progression. This condition produces low numbers of normal blood cells and the requirement of continuous need for transfusions Use in Cancer Gilteritinib fumarate is approved to treat: Acute myeloid leukemia that has relapsed (come back) or is refractory (does not respond to treatment). It is used in adults whose cancer has a mutation in the FLT3 gene. Gilteritinib fumarate is also being studied in the treatment of other types of cancer. Contraindications Hypersensitivity to the active component or any of the ingredients Safety and efficacy have not been established in patients younger than 18 years. low amount of magnesium in the blood low amount of potassium in the blood prolonged QT interval on EKG abnormal EKG with QT changes from birth pregnancy a patient who is producing milk and breastfeeding pancreatitis a type of brain disorder called posterior reversible encephalopathy syndrome Dosage Strengths: 40 mg Acute Myeloid Leukemia 120 mg orally once a day until disease progression or unacceptable toxicity The response may be delayed. In the absence of disease progression or unacceptable toxicity, patients should be treated for a minimum of 6 months to allow time for a clinical response. Select patients for the treatment of AML with this drug based on the presence of FLT3 mutations in the blood or bone marrow. Dose Adjustments DOSAGE MODIFICATIONS FOR TOXICITY: DIFFERENTIATION SYNDROME: If differentiation syndrome is suspected, administer systemic corticosteroids and initiate hemodynamic monitoring until symptom resolution and for a minimum of 3 days. Interrupt therapy if severe symptoms persist for more than 48 hours after initiation of corticosteroids. Resume therapy when symptoms improve to Grade 2 or lower. POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME: Discontinue therapy. QTc INTERVAL GREATER THAN 500 MSEC: Interrupt therapy; resume therapy at 80 mg orally once a day when QTc interval returns to within 30 msec of baseline or less than or equal to 480 msec. QTc INTERVAL INCREASED BY MORE THAN 30 MSEC ON ECG ON DAY 8 OF CYCLE 1: Confirm with ECG on Day 9; if confirmed, consider dose reduction to 80 mg orally once a day. Interrupt therapy until pancreatitis is resolved; resume therapy at 80 mg orally once a day. OTHER GRADE 3 OR HIGHER TOXICITY CONSIDERED RELATED TO TREATMENT: Interrupt therapy until toxicity resolves to Grade 1; resume therapy at 80 mg orally once a day. Administration advice: Do not break or crush tablets. This drug may be taken with or without food. Administer this drug at approximately the same time each day. If a dose is missed or not taken at the usual time, administer it as soon as possible on the same day, and at least 12 hours prior to the next scheduled dose; return to normal schedule the following day. Do not administer 2 doses within 12 hours. Side Effects The Most Common joint or muscle pain extreme tiredness nausea vomiting diarrhea mouth sores change in the ability to taste food headache loss of appetite difficulty falling asleep or staying asleep seizures; headache; decreased alertness; confusion; or vision changes fast, pounding, or irregular heartbeat; fainting; loss of consciousness; or seizures ongoing pain that begins in the stomach area but may spread to the back that may occur with or without nausea and vomiting More common Bloody urine blurred vision chest pain or tightness chills confusion cough decreased frequency or amount of urine dizziness dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position fainting fast or irregular heartbeat fever headache increased thirst lightheadedness loss of appetite lower back or side pain nausea nervousness pounding in the ears rapid, shallow breathing recurrent fainting slow heartbeat sneezing sore throat stomach pain sweating swelling of the face, fingers, or lower legs trouble breathing unusual tiredness or weakness vomiting weight gain Rare Anxiety blue or pale skin chest discomfort chest pain, possibly moving to the left arm, neck, or shoulder difficulty swallowing the action of the mouth trouble sleeping stomach pain painting fever fluid build-up around the lungs (e.g., chest pain, cough, hiccups, rapid breathing) increased frequency or severity of infections (symptoms may include fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness) inflammation of the mouth and lips low magnesium levels in the blood (e.g., weakness, tremors, muscle cramps, seizures) low potassium levels in the blood (e.g., weakness, fatigue, muscle cramps, irregular heartbeat) pain, numbness, or weakness in the hands and feet signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath) signs of clotting problems (e.g., unusual nosebleeds, bruising, blood in urine, coughing blood, bleeding gums, cuts that don't stop bleeding) signs of heart problems (e.g., fast, irregular heartbeat or pulse; chest pain; sudden weight gain; difficulty breathing; leg swelling) signs of kidney failure (e.g., decreased urine production, swelling, fatigue, abdominal pain) signs of kidney problems (e.g., change in the amount or color of urine, increased urination at night, blood in the urine, swelling in the feet or legs) symptoms of high blood sugar (e.g., frequent urination, increased thirst, excessive eating, unexplained weight loss, poor wound healing, infections, fruity breath odor) swelling in the feet, ankles, hands  vomiting, weakness shortness of breath fluid build-up around the heart (e.g., fever, fatigue, muscle aches, shortness of breath, nausea, vomiting, diarrhea, fast or pounding heartbeat, light-headedness) signs of an allergic reaction (e.g., wheezing, tightness in chest, troubled breathing, shortness of breath, or cough) signs of posterior reversible encephalopathy syndrome (e.g., headache, seizures, weakness, confusion, high blood pressure, vision changes, difficulty thinking clearly Drug Interactions DRUG INTERACTION Abaloparatide The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Gilteritinib. Abametapir The serum concentration of Gilteritinib can be increased when it is combined with Abametapir. Abatacept The metabolism of Gilteritinib can be increased when combined with Abatacept. Abemaciclib The excretion of Abemaciclib can be decreased when combined with Gilteritinib. Abrocitinib The serum concentration of Gilteritinib can be increased when it is combined with Abrocitinib. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Gilteritinib. Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Gilteritinib. Acetaminophen The serum concentration of Acetaminophen can be increased when it is combined with Gilteritinib. Acetazolamide The metabolism of Gilteritinib can be decreased when combined with Acetazolamide. Acetylcholine The risk or severity of adverse effects can be increased when Gilteritinib is combined with Acetylcholine. Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Gilteritinib. Acyclovir The risk or severity of adverse effects can be increased when Gilteritinib is combined with Acyclovir. Adalimumab The metabolism of Gilteritinib can be increased when combined with Adalimumab. Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Gilteritinib. Afatinib Gilteritinib may decrease the excretion rate of Afatinib which could result in a higher serum level. Agomelatine The therapeutic efficacy of Agomelatine can be decreased when used in combination with Gilteritinib. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Gilteritinib. Albendazole The metabolism of Gilteritinib can be decreased when combined with Albendazole. Aldesleukin The metabolism of Gilteritinib can be decreased when combined with Aldesleukin. Alectinib The metabolism of Alectinib can be decreased when combined with Gilteritinib. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Gilteritinib. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Gilteritinib. Allopurinol Gilteritinib may decrease the excretion rate of Allopurinol which could result in a higher serum level. Almotriptan The therapeutic efficacy of Almotriptan can be decreased when used in combination with Gilteritinib. Alosetron The therapeutic efficacy of Alosetron can be decreased when used in combination with Gilteritinib. Alpelisib The serum concentration of Alpelisib can be increased when it is combined with Gilteritinib. Alverine The therapeutic efficacy of Alverine can be decreased when used in combination with Gilteritinib. Amantadine The risk or severity of adverse effects can be increased when Gilteritinib is combined with Amantadine. Ambrisentan The serum concentration of Gilteritinib can be increased when it is combined with Ambrisentan. Amifampridine The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Gilteritinib. Aminoglutethimide The metabolism of Gilteritinib can be increased when combined with Aminoglutethimide. Aminophylline The metabolism of Aminophylline can be decreased when combined with Gilteritinib. Amiodarone The metabolism of Gilteritinib can be decreased when combined with Amiodarone. Amisulpride The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Amisulpride. Amitriptyline The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Gilteritinib. Amobarbital The metabolism of Gilteritinib can be increased when combined with Amobarbital. Amodiaquine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Gilteritinib. Amoxapine The therapeutic efficacy of Amoxapine can be decreased when used in combination with Gilteritinib. Amprenavir The metabolism of Gilteritinib can be decreased when combined with Amprenavir. Anagrelide The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Anagrelide. Anakinra The metabolism of Gilteritinib can be increased when combined with Anakinra. Antazoline The risk or severity of QTc prolongation can be increased when Antazoline is combined with Gilteritinib. Apalutamide The serum concentration of Gilteritinib can be decreased when it is combined with Apalutamide. Apixaban Gilteritinib may decrease the excretion rate of Apixaban which could result in a higher serum level. Apomorphine The therapeutic efficacy of Apomorphine can be decreased when used in combination with Gilteritinib. Apremilast The metabolism of Gilteritinib can be increased when combined with Apremilast. Aprepitant The metabolism of Gilteritinib can be decreased when combined with Aprepitant. Arformoterol The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Gilteritinib. Aripiprazole The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Gilteritinib. Aripiprazole The therapeutic efficacy of Aripiprazole lauroxil can be decreased when used in combination with Gilteritinib. Armodafinil The metabolism of Gilteritinib can be increased when combined with Armodafinil. Arsenic trioxide The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Arsenic trioxide. Artemether The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Artemether. Articaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Articaine. Asciminib The serum concentration of Gilteritinib can be increased when it is combined with Asciminib. Asenapine The therapeutic efficacy of Asenapine can be decreased when used in combination with Gilteritinib. Astemizole The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Astemizole. Asunaprevir The serum concentration of Gilteritinib can be increased when it is combined with Asunaprevir. Atazanavir The metabolism of Gilteritinib can be decreased when combined with Atazanavir. Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Gilteritinib. Atropine The risk or severity of QTc prolongation can be increased when Atropine is combined with Gilteritinib. Avacopan The metabolism of Gilteritinib can be decreased when combined with Avacopan. Avanafil The serum concentration of Avanafil can be increased when it is combined with Gilteritinib. Avatrombopag The serum concentration of Gilteritinib can be increased when it is combined with Avatrombopag. Axitinib The metabolism of Axitinib can be decreased when combined with Gilteritinib. Azatadine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Gilteritinib. Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Gilteritinib. Beclomethasone The metabolism of Gilteritinib can be increased when combined with Beclomethasone dipropionate. Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Gilteritinib. Belantamab The serum concentration of Belantamab mafodotin can be increased when it is combined with Gilteritinib. Belinostat The serum concentration of Gilteritinib can be increased when it is combined with Belinostat. Belumosudil The serum concentration of Gilteritinib can be increased when it is combined with Belumosudil. Bendamustine The serum concentration of Bendamustine can be increased when it is combined with Gilteritinib. Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Gilteritinib. Benzocaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Benzyl alcohol. Bepridil The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Bepridil. Berotralstat The serum concentration of Berotralstat can be increased when it is combined with Gilteritinib. Betamethasone The metabolism of Gilteritinib can be increased when combined with Betamethasone. Betamethasone The metabolism of Gilteritinib can be increased when combined with Betamethasone phosphate. Betrixaban The serum concentration of Betrixaban can be increased when it is combined with Gilteritinib. Bexarotene The metabolism of Gilteritinib can be increased when combined with Bexarotene. Bicalutamide The metabolism of Bicalutamide can be decreased when combined with Gilteritinib. Bifonazole The metabolism of Gilteritinib can be decreased when combined with Bifonazole. Bilastine The risk or severity of QTc prolongation can be increased when Bilastine is combined with Gilteritinib. Bimekizumab The metabolism of Gilteritinib can be increased when combined with Bimekizumab. Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Gilteritinib. Bisoprolol The serum concentration of Gilteritinib can be increased when it is combined with Bisoprolol. Boceprevir The metabolism of Gilteritinib can be decreased when combined with Boceprevir. Bortezomib The metabolism of Bortezomib can be decreased when combined with Gilteritinib. Bosentan The metabolism of Gilteritinib can be increased when combined with Bosentan. Bosutinib The metabolism of Bosutinib can be decreased when combined with Gilteritinib. Brentuximab The metabolism of Brentuximab vedotin can be decreased when combined with Gilteritinib. Bretylium The risk or severity of QTc prolongation can be increased when Bretylium is combined with Gilteritinib. Brexpiprazole The therapeutic efficacy of Brexpiprazole can be decreased when used in combination with Gilteritinib. Brigatinib The metabolism of Brigatinib can be decreased when combined with Gilteritinib. Bromocriptine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Gilteritinib. Brompheniramine The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Gilteritinib. Buclizine The risk or severity of QTc prolongation can be increased when Buclizine is combined with Gilteritinib. Budesonide The metabolism of Gilteritinib can be increased when combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Bupivacaine. Buprenorphine The metabolism of Gilteritinib can be decreased when combined with Buprenorphine. Buserelin The risk or severity of QTc prolongation can be increased when Buserelin is combined with Gilteritinib. Buspirone The therapeutic efficacy of Buspirone can be decreased when used in combination with Gilteritinib. Busulfan The metabolism of Busulfan can be decreased when combined with Gilteritinib. Butacaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Butacaine. Butalbital The metabolism of Gilteritinib can be increased when combined with Butalbital. Butamben The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Butamben. Butriptyline The therapeutic efficacy of Butriptyline can be decreased when used in combination with Gilteritinib. Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Gilteritinib. Cabergoline The therapeutic efficacy of Cabergoline can be decreased when used in combination with Gilteritinib. Calcitriol The metabolism of Gilteritinib can be increased when combined with Calcitriol. Canagliflozin The serum concentration of Gilteritinib can be increased when it is combined with Canagliflozin. Canakinumab The metabolism of Gilteritinib can be increased when combined with Canakinumab. Candicidin The metabolism of Gilteritinib can be decreased when combined with Candicidin. Cannabidiol The therapeutic efficacy of Cannabidiol can be decreased when used in combination with Gilteritinib. Capmatinib The serum concentration of Gilteritinib can be increased when it is combined with Capmatinib. Capsaicin The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Capsaicin. Carbamazepine The metabolism of Gilteritinib can be increased when combined with Carbamazepine. Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Gilteritinib. Carbinoxamine The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Gilteritinib. Carfilzomib The serum concentration of Gilteritinib can be increased when it is combined with Carfilzomib. Cariprazine The therapeutic efficacy of Cariprazine can be decreased when used in combination with Gilteritinib. Carvedilol The serum concentration of Gilteritinib can be increased when it is combined with Carvedilol. Cefradine The metabolism of Gilteritinib can be increased when combined with Cefradine. Celecoxib Gilteritinib may decrease the excretion rate of Celecoxib which could result in a higher serum level. Celiprolol The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Gilteritinib. Cenobamate The serum concentration of Gilteritinib can be decreased when it is combined with Cenobamate. Cephalexin The metabolism of Gilteritinib can be decreased when combined with Cephalexin. Ceritinib The metabolism of Ceritinib can be decreased when combined with Gilteritinib. Cerivastatin Gilteritinib may decrease the excretion rate of Cerivastatin which could result in a higher serum level. Certolizumab The metabolism of Gilteritinib can be increased when combined with Certolizumab pegol. Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Gilteritinib. Chloramphenicol The metabolism of Gilteritinib can be decreased when combined with Chloramphenicol. Chlorcyclizine The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Gilteritinib. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Chloroprocaine. Chloroquine The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Gilteritinib. Chlorpheniramine The therapeutic efficacy of Chlorpheniramine can be decreased when used in combination with Gilteritinib. Chlorpromazine The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Gilteritinib. Chlorprothixene The therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Gilteritinib. Choline The risk or severity of adverse effects can be increased when Gilteritinib is combined with Choline. Choline salicylate The risk or severity of adverse effects can be increased when Gilteritinib is combined with Choline salicylate. Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Gilteritinib. Cimetidine The risk or severity of adverse effects can be increased when Gilteritinib is combined with Cimetidine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Cinchocaine. Cinnarizine The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Gilteritinib. Cinoxacin The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Gilteritinib. Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Gilteritinib. Cisapride The therapeutic efficacy of Cisapride can be decreased when used in combination with Gilteritinib. Citalopram The therapeutic efficacy of Citalopram can be decreased when used in combination with Gilteritinib. Cladribine Gilteritinib may decrease the excretion rate of Cladribine which could result in a higher serum level. Clarithromycin The metabolism of Gilteritinib can be decreased when combined with Clarithromycin. Clemastine The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Clemastine. Clevidipine The metabolism of Gilteritinib can be increased when combined with Clevidipine. Clobazam The metabolism of Gilteritinib can be increased when combined with Clobazam. Clobetasol The metabolism of Gilteritinib can be increased when combined with Clobetasol propionate. Clofarabine Gilteritinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Clofazimine The serum concentration of Gilteritinib can be increased when it is combined with Clofazimine. Clofibrate The metabolism of Gilteritinib can be increased when combined with Clofibrate. Clomifene The serum concentration of Gilteritinib can be increased when it is combined with Clomifene. Clomipramine The therapeutic efficacy of Clomipramine can be decreased when used in combination with Gilteritinib. Clonidine The metabolism of Clonidine can be decreased when combined with Gilteritinib. Clozapine The therapeutic efficacy of Clozapine can be decreased when used in combination with Gilteritinib. Cobicistat The metabolism of Gilteritinib can be decreased when combined with Cobicistat. Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Gilteritinib. Cocaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Cocaine. Codeine The risk or severity of adverse effects can be increased when Gilteritinib is combined with Codeine. Colchicine The serum concentration of Gilteritinib can be increased when it is combined with Colchicine. Conivaptan The metabolism of Gilteritinib can be decreased when combined with Conivaptan. Conjugated Gilteritinib may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. Copanlisib The metabolism of Copanlisib can be decreased when combined with Gilteritinib. Corticotropin The metabolism of Gilteritinib can be increased when combined with Corticotropin. Cortisone acetate The metabolism of Gilteritinib can be increased when combined with Cortisone acetate. Crizotinib The metabolism of Crizotinib can be decreased when combined with Gilteritinib. Curcumin The metabolism of Gilteritinib can be decreased when combined with Curcumin. Cyclizine The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Gilteritinib. Cyclobenzaprine The therapeutic efficacy of Cyclobenzaprine can be decreased when used in combination with Gilteritinib. Cyclophosphamide The metabolism of Cyclophosphamide can be decreased when combined with Gilteritinib. Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Gilteritinib. Cyproheptadine The therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Gilteritinib. Cyproterone The metabolism of Gilteritinib can be decreased when combined with Cyproterone acetate. Cytarabine The risk or severity of adverse effects can be increased when Gilteritinib is combined with Cytarabine. Dabigatran The serum concentration of Gilteritinib can be increased when it is combined with Dabigatran etexilate. Dabrafenib The serum concentration of Gilteritinib can be decreased when it is combined with Dabrafenib. Daclatasvir The serum concentration of Gilteritinib can be increased when it is combined with Daclatasvir. Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Gilteritinib. Dactinomycin Gilteritinib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Dalfopristin The metabolism of Gilteritinib can be decreased when combined with Dalfopristin. Danazol The metabolism of Gilteritinib can be decreased when combined with Danazol. Daptomycin The serum concentration of Gilteritinib can be increased when it is combined with Daptomycin. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gilteritinib. Darolutamide Gilteritinib may decrease the excretion rate of Darolutamide which could result in a higher serum level. Darunavir The metabolism of Gilteritinib can be decreased when combined with Darunavir. Dasabuvir The serum concentration of Gilteritinib can be increased when it is combined with Dasabuvir. Dasatinib The metabolism of Dasatinib can be decreased when combined with Gilteritinib. Daunorubicin Gilteritinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Deferasirox The metabolism of Gilteritinib can be increased when combined with Deferasirox. Deflazacort The metabolism of Gilteritinib can be increased when combined with Deflazacort. Degarelix The risk or severity of QTc prolongation can be increased when Degarelix is combined with Gilteritinib. Delafloxacin Gilteritinib may decrease the excretion rate of Delafloxacin which could result in a higher serum level. Delamanid Gilteritinib may increase the QTc-prolonging activities of Delamanid. Delavirdine The metabolism of Gilteritinib can be decreased when combined with Delavirdine. Desflurane The risk or severity of QTc prolongation can be increased when Desflurane is combined with Gilteritinib. Desipramine The therapeutic efficacy of Desipramine can be decreased when used in combination with Gilteritinib. Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Gilteritinib. Desvenlafaxine The therapeutic efficacy of Desvenlafaxine can be decreased when used in combination with Gilteritinib. Deutetrabenazine The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Deutetrabenazine. Dexamethasone The metabolism of Gilteritinib can be increased when combined with Dexamethasone. Dexamethasone The metabolism of Gilteritinib can be increased when combined with Dexamethasone acetate. Dexbromphenira The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Gilteritinib. Dexchlorpheniram The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Gilteritinib. Dexmethylphenid The therapeutic efficacy of Dexmethylphenidate can be decreased when used in combination with Gilteritinib. Dextromethorphan The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with Gilteritinib. Dextropropoxy The metabolism of Gilteritinib can be decreased when combined with Dextropropoxyphene. Dicloxacillin The metabolism of Gilteritinib can be increased when combined with Dicloxacillin. Diethylstilbestrol The metabolism of Gilteritinib can be decreased when combined with Diethylstilbestrol. Difluocortolone The metabolism of Gilteritinib can be increased when combined with Difluocortolone. Digitoxin The metabolism of Digitoxin can be decreased when combined with Gilteritinib. Digoxin The serum concentration of Digoxin can be increased when it is combined with Gilteritinib. Dihydroergocornine The metabolism of Gilteritinib can be decreased when combined with Dihydroergocornine. Dihydroergocristine The metabolism of Dihydroergocristine can be decreased when combined with Gilteritinib. Dihydroergotamine The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Gilteritinib. Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Gilteritinib. Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Gilteritinib. Dimethyl sulfoxide The metabolism of Gilteritinib can be decreased when combined with Dimethyl sulfoxide. Diosmin The serum concentration of Gilteritinib can be increased when it is combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Diphenhydramine. Disopyramide The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Disopyramide. Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Gilteritinib. Docetaxel The metabolism of Docetaxel can be decreased when combined with Gilteritinib. Dofetilide The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Dofetilide. Dolasetron The therapeutic efficacy of Dolasetron can be decreased when used in combination with Gilteritinib. Dolutegravir Gilteritinib may decrease the excretion rate of Dolutegravir which could result in a higher serum level. Domperidone The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Domperidone. Donepezil Gilteritinib may decrease the excretion rate of Donepezil which could result in a higher serum level. Dopamine The risk or severity of adverse effects can be increased when Gilteritinib is combined with Dopamine. Dosulepin The therapeutic efficacy of Dosulepin can be decreased when used in combination with Gilteritinib. Doxazosin The metabolism of Gilteritinib can be decreased when combined with Doxazosin. Doxepin The therapeutic efficacy of Doxepin can be decreased when used in combination with Gilteritinib. Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Gilteritinib. Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Gilteritinib. Dronedarone The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Dronedarone. Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Gilteritinib. Drospirenone The metabolism of Gilteritinib can be decreased when combined with Drospirenone. Duloxetine The therapeutic efficacy of Duloxetine can be decreased when used in combination with Gilteritinib. Duvelisib Gilteritinib may decrease the excretion rate of Duvelisib which could result in a higher serum level. Dyclonine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Dyclonine. Ebastine The metabolism of Gilteritinib can be decreased when combined with Ebastine. Echinacea The metabolism of Gilteritinib can be increased when combined with Echinacea. Edoxaban The serum concentration of Gilteritinib can be increased when it is combined with Edoxaban. Efavirenz The metabolism of Gilteritinib can be decreased when combined with Efavirenz. Elagolix The serum concentration of Gilteritinib can be increased when it is combined with Elagolix. Elbasvir The serum concentration of Gilteritinib can be increased when it is combined with Elbasvir. Eletriptan The therapeutic efficacy of Eletriptan can be decreased when used in combination with Gilteritinib. Elexacaftor The metabolism of Elexacaftor can be decreased when combined with Gilteritinib. Eliglustat The serum concentration of Gilteritinib can be increased when it is combined with Eliglustat. Elvitegravir The metabolism of Gilteritinib can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Gilteritinib can be increased when combined with Emapalumab. Emedastine The risk or severity of QTc prolongation can be increased when Emedastine is combined with Gilteritinib. Emtricitabine The excretion of Emtricitabine can be decreased when combined with Gilteritinib. Enasidenib The metabolism of Enasidenib can be decreased when combined with Gilteritinib. Encainide The risk or severity of QTc prolongation can be increased when Encainide is combined with Gilteritinib. Encorafenib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Gilteritinib. Enfortumab The serum concentration of Enfortumab vedotin can be increased when it is combined with Gilteritinib. Enoxacin The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Gilteritinib. Entrectinib The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Entrectinib. Enzalutamide The serum concentration of Gilteritinib can be decreased when it is combined with Enzalutamide. Epinastine The therapeutic efficacy of Epinastine can be decreased when used in combination with Gilteritinib. Epinephrine The metabolism of Gilteritinib can be decreased when combined with Epinephrine. Erdafitinib The serum concentration of Gilteritinib can be increased when it is combined with Erdafitinib. Ergoloid mesylate The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Gilteritinib. Ergometrine The therapeutic efficacy of Ergometrine can be decreased when used in combination with Gilteritinib. Ergotamine The therapeutic efficacy of Ergotamine can be decreased when used in combination with Gilteritinib. Eribulin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Gilteritinib. Erlotinib The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Erlotinib. Ertugliflozin Gilteritinib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level. Erythromycin The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Gilteritinib. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Gilteritinib. Escitalopram The therapeutic efficacy of Escitalopram can be decreased when used in combination with Gilteritinib. Esketamine The metabolism of Gilteritinib can be increased when combined with Esketamine. Eslicarbazepine The metabolism of Gilteritinib can be increased when combined with Eslicarbazepine. Eslicarbazepine The metabolism of Gilteritinib can be increased when combined with Eslicarbazepine acetate. Esmolol The risk or severity of QTc prolongation can be increased when Esmolol is combined with Gilteritinib. Estetrol The metabolism of Estetrol can be decreased when combined with Gilteritinib. Estradiol acetate The metabolism of Gilteritinib can be increased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Gilteritinib can be increased when combined with Estradiol benzoate. Estradiol cypionate The metabolism of Gilteritinib can be increased when combined with Estradiol cypionate. Estradiol The metabolism of Gilteritinib can be increased when combined with Estradiol dienanthate. Estradiol valerate The metabolism of Gilteritinib can be increased when combined with Estradiol valerate. Estrone sulfate The excretion of Estrone sulfate can be decreased when combined with Gilteritinib. Etanercept The metabolism of Gilteritinib can be increased when combined with Etanercept. Ethambutol The metabolism of Gilteritinib can be decreased when combined with Ethambutol. Ethanol The metabolism of Gilteritinib can be increased when combined with Ethanol. Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Gilteritinib. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Etidocaine. Etoposide The metabolism of Etoposide can be decreased when combined with Gilteritinib. Etoricoxib The metabolism of Gilteritinib can be decreased when combined with Etoricoxib. Etravirine The metabolism of Gilteritinib can be increased when combined with Etravirine. Everolimus The metabolism of Everolimus can be decreased when combined with Gilteritinib. Ezetimibe Gilteritinib may decrease the excretion rate of Ezetimibe which could result in a higher serum level. Ezogabine The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Gilteritinib. Famotidine The risk or severity of QTc prolongation can be increased when Famotidine is combined with Gilteritinib. Favipiravir The serum concentration of Gilteritinib can be increased when it is combined with Favipiravir. Fedratinib The serum concentration of Gilteritinib can be increased when it is combined with Fedratinib. Felbamate The metabolism of Gilteritinib can be increased when combined with Felbamate. Felodipine The risk or severity of QTc prolongation can be increased when Felodipine is combined with Gilteritinib. Fenfluramine The therapeutic efficacy of Fenfluramine can be decreased when used in combination with Gilteritinib. Fenofibrate The metabolism of Gilteritinib can be decreased when combined with Fenofibrate. Fentanyl The therapeutic efficacy of Fentanyl can be decreased when used in combination with Gilteritinib. Fexinidazole The risk or severity of adverse effects can be increased when Gilteritinib is combined with Fexinidazole. Fexofenadine The serum concentration of Gilteritinib can be increased when it is combined with Fexofenadine. Flecainide The risk or severity of QTc prolongation can be increased when Flecainide is combined with Gilteritinib. Flibanserin The therapeutic efficacy of Flibanserin can be decreased when used in combination with Gilteritinib. Flucloxacillin The metabolism of Gilteritinib can be increased when combined with Flucloxacillin. Fluconazole The metabolism of Gilteritinib can be decreased when combined with Fluconazole. Flunisolide The metabolism of Gilteritinib can be increased when combined with Flunisolide. Fluocinolone The metabolism of Gilteritinib can be increased when combined with Fluocinolone acetonide. Fluocinonide The metabolism of Gilteritinib can be increased when combined with Fluocinonide. Fluocortolone The metabolism of Gilteritinib can be increased when combined with Fluocortolone. Fluorouracil The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Gilteritinib. Fluoxetine The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Gilteritinib. Flupentixol The therapeutic efficacy of Flupentixol can be decreased when used in combination with Gilteritinib. Fluspirilene The therapeutic efficacy of Fluspirilene can be decreased when used in combination with Gilteritinib. Fluticasone The metabolism of Gilteritinib can be increased when combined with Fluticasone. Fluticasone The metabolism of Gilteritinib can be increased when combined with Fluticasone furoate. Fluticasone The metabolism of Gilteritinib can be decreased when combined with Fluticasone propionate. Fluvoxamine The therapeutic efficacy of Fluvoxamine can be decreased when used in combination with Gilteritinib. Folic acid Gilteritinib may decrease the excretion rate of Folic acid which could result in a higher serum level. Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Gilteritinib. Formestane The metabolism of Gilteritinib can be increased when combined with Formestane. Formoterol The risk or severity of adverse effects can be increased when Gilteritinib is combined with Formoterol. Fosamprenavir The metabolism of Gilteritinib can be decreased when combined with Fosamprenavir. Fosaprepitant The metabolism of Gilteritinib can be increased when combined with Fosaprepitant. Foscarnet The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Gilteritinib. Fosnetupitant The metabolism of Gilteritinib can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Gilteritinib can be increased when combined with Fosphenytoin. Fostamatinib The metabolism of Gilteritinib can be decreased when combined with Fostamatinib. Fostemsavir Gilteritinib may decrease the excretion rate of Fostemsavir which could result in a higher serum level. Frovatriptan The therapeutic efficacy of Frovatriptan can be decreased when used in combination with Gilteritinib. Fusidic acid The metabolism of Gilteritinib can be decreased when combined with Fusidic acid. Futibatinib The serum concentration of Futibatinib can be increased when it is combined with Gilteritinib. Gadobenic acid The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Gilteritinib. Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Gilteritinib. Ganciclovir The risk or severity of adverse effects can be increased when Gilteritinib is combined with Ganciclovir. Gatifloxacin The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Gilteritinib. Gefitinib Gilteritinib may decrease the excretion rate of Gefitinib which could result in a higher serum level. Gemcitabine The serum concentration of Gemcitabine can be increased when it is combined with Gilteritinib. Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Gilteritinib. Ginkgo biloba The metabolism of Gilteritinib can be decreased when combined with Ginkgo biloba. Glasdegib The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Glasdegib. Glecaprevir Gilteritinib may decrease the excretion rate of Glecaprevir which could result in a higher serum level. Glyburide Gilteritinib may decrease the excretion rate of Glyburide which could result in a higher serum level. Glycerol The metabolism of Gilteritinib can be increased when combined with Glycerol phenylbutyrate. Golimumab The metabolism of Gilteritinib can be increased when combined with Golimumab. Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Gilteritinib. Granisetron The therapeutic efficacy of Granisetron can be decreased when used in combination with Gilteritinib. Grazoprevir The serum concentration of Gilteritinib can be increased when it is combined with Grazoprevir. Grepafloxacin The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Grepafloxacin. Griseofulvin The metabolism of Gilteritinib can be increased when combined with Griseofulvin. Guanfacine The risk or severity of adverse effects can be increased when Gilteritinib is combined with Guanfacine. Guanidine The excretion of Guanidine can be decreased when combined with Gilteritinib. Halofantrine The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Halofantrine. Haloperidol The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Haloperidol. Histamine The risk or severity of adverse effects can be increased when Gilteritinib is combined with Histamine. Histrelin The risk or severity of QTc prolongation can be increased when Histrelin is combined with Gilteritinib. Hydralazine The metabolism of Gilteritinib can be decreased when combined with Hydralazine. Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Gilteritinib. Hydrocortamate The metabolism of Gilteritinib can be increased when combined with Hydrocortamate. Hydrocortisone The metabolism of Gilteritinib can be increased when combined with Hydrocortisone. Hydrocortisone The metabolism of Gilteritinib can be increased when combined with Hydrocortisone acetate. Hydrocortisone The metabolism of Gilteritinib can be increased when combined with Hydrocortisone butyrate. Hydrocortisone The metabolism of Gilteritinib can be increased when combined with Hydrocortisone succinate. Hydroxychloroq The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Gilteritinib. Hydroxyzine The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Hydroxyzine. Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Gilteritinib. Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Gilteritinib. Ibutilide The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Ibutilide. Idelalisib The metabolism of Idelalisib can be decreased when combined with Gilteritinib. Ifosfamide The metabolism of Ifosfamide can be decreased when combined with Gilteritinib. Iloperidone The therapeutic efficacy of Iloperidone can be decreased when used in combination with Gilteritinib. Imatinib The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Imatinib. Imipramine The therapeutic efficacy of Imipramine can be decreased when used in combination with Gilteritinib. Indacaterol The serum concentration of Gilteritinib can be increased when it is combined with Indacaterol. Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Gilteritinib. Indinavir The metabolism of Gilteritinib can be decreased when combined with Indinavir. Infigratinib The metabolism of Gilteritinib can be decreased when combined with Infigratinib. Infliximab The metabolism of Gilteritinib can be increased when combined with Infliximab. Inotersen The risk or severity of QTc prolongation can be increased when Inotersen is combined with Gilteritinib. Inotuzumab The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Gilteritinib. Irbesartan The metabolism of Gilteritinib can be decreased when combined with Irbesartan. Irinotecan The metabolism of Irinotecan can be decreased when combined with Gilteritinib. Isavuconazole The serum concentration of Gilteritinib can be increased when it is combined with Isavuconazole. Isavuconazonium The serum concentration of Gilteritinib can be increased when it is combined with Isavuconazonium. Isocarboxazid The therapeutic efficacy of Isocarboxazid can be decreased when used in combination with Gilteritinib. Isoflurane The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Gilteritinib. Isoniazid The metabolism of Gilteritinib can be decreased when combined with Isoniazid. Isradipine The metabolism of Gilteritinib can be decreased when combined with Isradipine. Istradefylline The serum concentration of Gilteritinib can be increased when it is combined with Istradefylline. Itraconazole The metabolism of Gilteritinib can be decreased when combined with Itraconazole. Ivabradine Ivabradine may increase the QTc-prolonging activities of Gilteritinib. Ivacaftor The serum concentration of Gilteritinib can be increased when it is combined with Ivacaftor. Ivermectin Gilteritinib may decrease the excretion rate of Ivermectin which could result in a higher serum level. Ivosidenib The metabolism of Gilteritinib can be increased when combined with Ivosidenib. Ixabepilone The metabolism of Ixabepilone can be decreased when combined with Gilteritinib. Ixazomib The metabolism of Ixazomib can be decreased when combined with Gilteritinib. Ketazolam The metabolism of Gilteritinib can be decreased when combined with Ketazolam. Ketoconazole The metabolism of Gilteritinib can be decreased when combined with Ketoconazole. Lacidipine The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Gilteritinib. Lacosamide The metabolism of Gilteritinib can be decreased when combined with Lacosamide. Lamivudine Gilteritinib may decrease the excretion rate of Lamivudine which could result in a higher serum level. Lamotrigine The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Gilteritinib. Lanreotide The metabolism of Gilteritinib can be decreased when combined with Lanreotide. Lapatinib The serum concentration of Gilteritinib can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Larotrectinib can be increased when it is combined with Gilteritinib. Lasmiditan The therapeutic efficacy of Lasmiditan can be decreased when used in combination with Gilteritinib. Ledipasvir The serum concentration of Gilteritinib can be increased when it is combined with Ledipasvir. Lefamulin Lefamulin may increase the QTc-prolonging activities of Gilteritinib. Leflunomide Gilteritinib may decrease the excretion rate of Leflunomide which could result in a higher serum level. Lemborexant The serum concentration of Gilteritinib can be increased when it is combined with Lemborexant. Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Gilteritinib. Lesinurad The metabolism of Gilteritinib can be increased when combined with Lesinurad. Letermovir The metabolism of Gilteritinib can be decreased when combined with Letermovir. Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Gilteritinib. Levacetylmethadol The metabolism of Levacetylmethadol can be decreased when combined with Gilteritinib. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Levobupivacaine. Levocabastine The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Gilteritinib. Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Gilteritinib. Levofloxacin The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Gilteritinib. Levoketoconazole The metabolism of Gilteritinib can be decreased when combined with Levoketoconazole. Levomenthol The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Gilteritinib. Levomilnacipran The therapeutic efficacy of Levomilnacipran can be decreased when used in combination with Gilteritinib. Levosimendan The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Gilteritinib. Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Gilteritinib. Lidocaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Lidocaine. Lidoflazine The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Gilteritinib. Linagliptin The metabolism of Gilteritinib can be decreased when combined with Linagliptin. Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Gilteritinib. Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Gilteritinib. Lisuride The therapeutic efficacy of Lisuride can be decreased when used in combination with Gilteritinib. Lofexidine The therapeutic efficacy of Lofexidine can be decreased when used in combination with Gilteritinib. Lomefloxacin The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Gilteritinib. Lomitapide The metabolism of Lomitapide can be decreased when combined with Gilteritinib. Lonafarnib The metabolism of Gilteritinib can be decreased when combined with Lonafarnib. Loncastuximab The serum concentration of Loncastuximab tesirine can be increased when it is combined with Gilteritinib. Loperamide The risk or severity of QTc prolongation can be increased when Loperamide is combined with Gilteritinib. Lopinavir The metabolism of Gilteritinib can be decreased when combined with Lopinavir. Lorcaserin The therapeutic efficacy of Lorcaserin can be decreased when used in combination with Gilteritinib. Lorlatinib The metabolism of Gilteritinib can be increased when combined with Lorlatinib. Losartan The metabolism of Gilteritinib can be decreased when combined with Losartan. Lovastatin The metabolism of Gilteritinib can be decreased when combined with Lovastatin. Loxapine The therapeutic efficacy of Loxapine can be decreased when used in combination with Gilteritinib. Lumacaftor The serum concentration of Gilteritinib can be decreased when it is combined with Lumacaftor. Lumefantrine The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Lumefantrine. Lurasidone The therapeutic efficacy of Lurasidone can be decreased when used in combination with Gilteritinib. Lusutrombopag Gilteritinib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level. Macimorelin The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Macimorelin. Manidipine The metabolism of Gilteritinib can be decreased when combined with Manidipine. Mannitol The serum concentration of Gilteritinib can be increased when it is combined with Mannitol. Maprotiline The therapeutic efficacy of Maprotiline can be decreased when used in combination with Gilteritinib. Maribavir The serum concentration of Gilteritinib can be increased when it is combined with Maribavir. Mavacamten The serum concentration of Gilteritinib can be decreased when it is combined with Mavacamten. Mazindol The therapeutic efficacy of Mazindol can be decreased when used in combination with Gilteritinib. Medroxyproges The metabolism of Gilteritinib can be increased when combined with Medroxyprogesterone acetate. Mefloquine The serum concentration of Gilteritinib can be increased when it is combined with Mefloquine. Meloxicam The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Meloxicam. Meperidine The therapeutic efficacy of Meperidine can be decreased when used in combination with Gilteritinib. Mepivacaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Mepivacaine. Meprednisone The metabolism of Gilteritinib can be increased when combined with Meprednisone. Mepyramine The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Gilteritinib. Mesoridazine The therapeutic efficacy of Mesoridazine can be decreased when used in combination with Gilteritinib. Metergoline The therapeutic efficacy of Metergoline can be decreased when used in combination with Gilteritinib. Metformin The excretion of Metformin can be decreased when combined with Gilteritinib. Methadone The therapeutic efficacy of Methadone can be decreased when used in combination with Gilteritinib. Methimazole The metabolism of Gilteritinib can be decreased when combined with Methimazole. Methotrexate The metabolism of Methotrexate can be decreased when combined with Gilteritinib. Methotrimeprazine The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Gilteritinib. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gilteritinib. Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Gilteritinib. Methylene blue The serum concentration of Gilteritinib can be increased when it is combined with Methylene blue. Methylergometrine The metabolism of Gilteritinib can be decreased when combined with Methylergometrine. Methylphenobarbital The metabolism of Gilteritinib can be increased when combined with Methylphenobarbital. Methylprednisolone The metabolism of Gilteritinib can be increased when combined with Methylprednisolone. Methylprednisone The metabolism of Methylprednisone can be decreased when combined with Gilteritinib. Methysergide The therapeutic efficacy of Methysergide can be decreased when used in combination with Gilteritinib. Metoclopramide The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Gilteritinib. Metreleptin The metabolism of Gilteritinib can be increased when combined with Metreleptin. Metronidazole The metabolism of Gilteritinib can be decreased when combined with Metronidazole. Metyrapone The metabolism of Gilteritinib can be increased when combined with Metyrapone. Mianserin The therapeutic efficacy of Mianserin can be decreased when used in combination with Gilteritinib. Miconazole The metabolism of Gilteritinib can be decreased when combined with Miconazole. Midazolam The metabolism of Gilteritinib can be decreased when combined with Midazolam. Midostaurin The metabolism of Gilteritinib can be decreased when combined with Midostaurin. Mifepristone The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Mifepristone. Milnacipran The therapeutic efficacy of Milnacipran can be decreased when used in combination with Gilteritinib. Miocamycin The metabolism of Gilteritinib can be decreased when combined with Miocamycin. Mirabegron The serum concentration of Gilteritinib can be increased when it is combined with Mirabegron. Mirtazapine The therapeutic efficacy of Mirtazapine can be decreased when used in combination with Gilteritinib. Mitapivat The serum concentration of Gilteritinib can be increased when it is combined with Mitapivat. Mitotane The metabolism of Gilteritinib can be increased when combined with Mitotane. Mitoxantrone Gilteritinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level. Mizolastine The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Mizolastine. Mobocertinib The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Mobocertinib. Moclobemide The therapeutic efficacy of Moclobemide can be decreased when used in combination with Gilteritinib. Modafinil The metabolism of Gilteritinib can be increased when combined with Modafinil. Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Gilteritinib. Molindone The therapeutic efficacy of Molindone can be decreased when used in combination with Gilteritinib. Mometasone The metabolism of Gilteritinib can be increased when combined with Mometasone furoate. Moricizine The risk or severity of QTc prolongation can be increased when Moricizine is combined with Gilteritinib. Morphine The serum concentration of Gilteritinib can be increased when it is combined with Morphine. Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Gilteritinib. Mycophenolate Gilteritinib may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level. Nadolol The excretion of Nadolol can be decreased when combined with Gilteritinib. Nafcillin The metabolism of Gilteritinib can be increased when combined with Nafcillin. Nalidixic acid The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Gilteritinib. Naloxone The metabolism of Gilteritinib can be decreased when combined with Naloxone. Naratriptan The therapeutic efficacy of Naratriptan can be decreased when used in combination with Gilteritinib. Nefazodone The therapeutic efficacy of Nefazodone can be decreased when used in combination with Gilteritinib. Nelfinavir The metabolism of Gilteritinib can be decreased when combined with Nelfinavir. Neratinib The metabolism of Neratinib can be decreased when combined with Gilteritinib. Netupitant The metabolism of Gilteritinib can be decreased when combined with Netupitant. Niacin The metabolism of Gilteritinib can be decreased when combined with Niacin. Nicardipine The metabolism of Gilteritinib can be decreased when combined with Nicardipine. Nifedipine The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Gilteritinib. Nilotinib The metabolism of Gilteritinib can be decreased when combined with Nilotinib. Nilvadipine The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Gilteritinib. Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Gilteritinib. Nintedanib The metabolism of Gilteritinib can be decreased when combined with Nintedanib. Nitrendipine The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Gilteritinib. Nitrofurantoin Gilteritinib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. Norepinephrine The risk or severity of adverse effects can be increased when Gilteritinib is combined with Norepinephrine. Norethisterone The metabolism of Gilteritinib can be decreased when combined with Norethisterone. Norfloxacin The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Gilteritinib. Norgestimate The serum concentration of Gilteritinib can be increased when it is combined with Norgestimate. Nortriptyline The therapeutic efficacy of Nortriptyline can be decreased when used in combination with Gilteritinib. Noscapine The metabolism of Gilteritinib can be decreased when combined with Noscapine. Octreotide The metabolism of Gilteritinib can be decreased when combined with Octreotide. Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Gilteritinib. Olanzapine The therapeutic efficacy of Olanzapine can be decreased when used in combination with Gilteritinib. Olaparib The metabolism of Olaparib can be decreased when combined with Gilteritinib. Olodaterol The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Gilteritinib. Omadacycline The serum concentration of Omadacycline can be increased when it is combined with Gilteritinib. Ombitasvir Gilteritinib may decrease the excretion rate of Ombitasvir which could result in a higher serum level. Omeprazole The metabolism of Gilteritinib can be increased when combined with Omeprazole. Ondansetron The therapeutic efficacy of Ondansetron can be decreased when used in combination with Gilteritinib. Oritavancin The metabolism of Gilteritinib can be increased when combined with Oritavancin. Orphenadrine The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Gilteritinib. Osilodrostat The metabolism of Gilteritinib can be decreased when combined with Osilodrostat. Osimertinib The metabolism of Osimertinib can be decreased when combined with Gilteritinib. Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Gilteritinib. Oxatomide The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Oxatomide. Oxcarbazepine The metabolism of Gilteritinib can be increased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Oxybuprocaine. Oxybutynin The metabolism of Gilteritinib can be decreased when combined with Oxybutynin. Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gilteritinib. Ozanimod Gilteritinib may decrease the excretion rate of Ozanimod which could result in a higher serum level. Paclitaxel The metabolism of Paclitaxel can be decreased when combined with Gilteritinib. Pacritinib The serum concentration of Gilteritinib can be increased when it is combined with Pacritinib. Palbociclib The metabolism of Palbociclib can be decreased when combined with Gilteritinib. Paliperidone The therapeutic efficacy of Paliperidone can be decreased when used in combination with Gilteritinib. Palonosetron The therapeutic efficacy of Palonosetron can be decreased when used in combination with Gilteritinib. Pancuronium The risk or severity of adverse effects can be increased when Gilteritinib is combined with Pancuronium. Panobinostat The metabolism of Panobinostat can be decreased when combined with Gilteritinib. Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Gilteritinib. Parathyroid The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Gilteritinib. Paritaprevir The serum concentration of Gilteritinib can be increased when it is combined with Paritaprevir. Paroxetine The therapeutic efficacy of Paroxetine can be decreased when used in combination with Gilteritinib. Pasireotide The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Gilteritinib. Pazopanib The metabolism of Pazopanib can be decreased when combined with Gilteritinib. Pefloxacin The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Gilteritinib. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Gilteritinib. Penbutolol The therapeutic efficacy of Penbutolol can be decreased when used in combination with Gilteritinib. Pentamidine The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Gilteritinib. Pentobarbital The metabolism of Gilteritinib can be increased when combined with Pentobarbital. Perampanel The metabolism of Gilteritinib can be increased when combined with Perampanel. Perflutren The risk or severity of QTc prolongation can be increased when Perflutren is combined with Gilteritinib. Pergolide The therapeutic efficacy of Pergolide can be decreased when used in combination with Gilteritinib. Perhexiline The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Gilteritinib. Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Gilteritinib. Phenelzine The therapeutic efficacy of Phenelzine can be decreased when used in combination with Gilteritinib. Phenformin The risk or severity of adverse effects can be increased when Gilteritinib is combined with Phenformin. Pheniramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Gilteritinib. Phenobarbital The metabolism of Gilteritinib can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Phenol. Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Gilteritinib. Phenylbutazone The metabolism of Gilteritinib can be increased when combined with Phenylbutazone. Phenytoin The metabolism of Gilteritinib can be increased when combined with Phenytoin. Pibrentasvir Gilteritinib may decrease the excretion rate of Pibrentasvir which could result in a higher serum level. Pimavanserin The therapeutic efficacy of Pimavanserin can be decreased when used in combination with Gilteritinib. Pimozide The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Pimozide. Pinaverium The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Gilteritinib. Pindolol The therapeutic efficacy of Pindolol can be decreased when used in combination with Gilteritinib. Piperaquine The metabolism of Gilteritinib can be decreased when combined with Piperaquine. Pitavastatin Gilteritinib may decrease the excretion rate of Pitavastatin which could result in a higher serum level. Pitolisant The serum concentration of Gilteritinib can be decreased when it is combined with Pitolisant. Pizotifen The therapeutic efficacy of Pizotifen can be decreased when used in combination with Gilteritinib. Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Gilteritinib. Ponatinib The metabolism of Ponatinib can be decreased when combined with Gilteritinib. Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Gilteritinib. Posaconazole The metabolism of Gilteritinib can be decreased when combined with Posaconazole. Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Gilteritinib. Potassium The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Gilteritinib. Pralatrexate Gilteritinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pralsetinib Gilteritinib may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Pramipexole The risk or severity of adverse effects can be increased when Gilteritinib is combined with Pramipexole. Pramocaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Pramocaine. Pravastatin Gilteritinib may decrease the excretion rate of Pravastatin which could result in a higher serum level. Prazosin Gilteritinib may decrease the excretion rate of Prazosin which could result in a higher serum level. Prednisolone The metabolism of Gilteritinib can be increased when combined with Prednisolone. Prednisolone The metabolism of Gilteritinib can be increased when combined with Prednisolone acetate. Prednisolone The metabolism of Gilteritinib can be increased when combined with Prednisolone phosphate. Prednisone acet The metabolism of Gilteritinib can be increased when combined with Prednisone acetate. Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Gilteritinib. Prenylamine The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Gilteritinib. Pretomanid The metabolism of Gilteritinib can be decreased when combined with Pretomanid. Prilocaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Prilocaine. Primaquine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Gilteritinib. Primidone The metabolism of Gilteritinib can be increased when combined with Primidone. Probenecid The metabolism of Gilteritinib can be increased when combined with Probenecid. Probucol The risk or severity of QTc prolongation can be increased when Probucol is combined with Gilteritinib. Procainamide The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Procainamide. Procaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Procaine. Procarbazine The therapeutic efficacy of Procarbazine can be decreased when used in combination with Gilteritinib. Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Gilteritinib. Promazine The therapeutic efficacy of Promazine can be decreased when used in combination with Gilteritinib. Promethazine The therapeutic efficacy of Promethazine can be decreased when used in combination with Gilteritinib. Propafenone The risk or severity of QTc prolongation can be increased when Propafenone is combined with Gilteritinib. Proparacaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Proparacaine. Propiomazine The therapeutic efficacy of Propiomazine can be decreased when used in combination with Gilteritinib. Propofol The risk or severity of QTc prolongation can be increased when Propofol is combined with Gilteritinib. Propoxycaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Propoxycaine. Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Gilteritinib. Protirelin The therapeutic efficacy of Protirelin can be decreased when used in combination with Gilteritinib. Protriptyline The therapeutic efficacy of Protriptyline can be decreased when used in combination with Gilteritinib. Prucalopride The therapeutic efficacy of Prucalopride can be decreased when used in combination with Gilteritinib. Quetiapine The therapeutic efficacy of Quetiapine can be decreased when used in combination with Gilteritinib. Quinidine The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Quinidine. Quinine The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Quinine. Quinupristin The metabolism of Gilteritinib can be decreased when combined with Quinupristin. Raloxifene Gilteritinib may decrease the excretion rate of Raloxifene which could result in a higher serum level. Ranitidine The risk or severity of adverse effects can be increased when Gilteritinib is combined with Ranitidine. Ranolazine The serum concentration of Gilteritinib can be increased when it is combined with Ranolazine. Rasagiline The therapeutic efficacy of Rasagiline can be decreased when used in combination with Gilteritinib. Regorafenib The metabolism of Regorafenib can be decreased when combined with Gilteritinib. Relebactam The excretion of Relebactam can be decreased when combined with Gilteritinib. Relugolix The serum concentration of Gilteritinib can be increased when it is combined with Relugolix. Remdesivir The metabolism of Gilteritinib can be decreased when combined with Remdesivir. Reserpine The serum concentration of Gilteritinib can be increased when it is combined with Reserpine. Revefenacin Gilteritinib may decrease the excretion rate of Revefenacin which could result in a higher serum level. Ribociclib The metabolism of Gilteritinib can be decreased when combined with Ribociclib. Rifabutin The metabolism of Gilteritinib can be increased when combined with Rifabutin. Rifampicin The metabolism of Gilteritinib can be increased when combined with Rifampicin. Rifamycin The metabolism of Gilteritinib can be increased when combined with Rifamycin. Rifapentine The metabolism of Gilteritinib can be increased when combined with Rifapentine. Rilonacept The metabolism of Gilteritinib can be increased when combined with Rilonacept. Rilpivirine The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Gilteritinib. Riluzole Gilteritinib may decrease the excretion rate of Riluzole which could result in a higher serum level. Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Gilteritinib. Riociguat Gilteritinib may decrease the excretion rate of Riociguat which could result in a higher serum level. Ripretinib Gilteritinib may decrease the excretion rate of Ripretinib which could result in a higher serum level. Risperidone The therapeutic efficacy of Risperidone can be decreased when used in combination with Gilteritinib. Ritonavir The serum concentration of Gilteritinib can be increased when it is combined with Ritonavir. Rivaroxaban Gilteritinib may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. Rizatriptan The therapeutic efficacy of Rizatriptan can be decreased when used in combination with Gilteritinib. Rocuronium The risk or severity of adverse effects can be increased when Gilteritinib is combined with Rocuronium. Rofecoxib The metabolism of Gilteritinib can be increased when combined with Rofecoxib. Roflumilast The metabolism of Gilteritinib can be decreased when combined with Roflumilast. Rolapitant The serum concentration of Gilteritinib can be increased when it is combined with Rolapitant. Romidepsin The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Romidepsin. Ropivacaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Ropivacaine. Rosoxacin The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Gilteritinib. Rosuvastatin Gilteritinib may decrease the excretion rate of Rosuvastatin which could result in a higher serum level. Rotigotine The therapeutic efficacy of Rotigotine can be decreased when used in combination with Gilteritinib. Roxithromycin The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Gilteritinib. Rucaparib Gilteritinib may decrease the excretion rate of Rucaparib which could result in a higher serum level. Rufinamide The metabolism of Gilteritinib can be increased when combined with Rufinamide. Rupatadine The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Gilteritinib. Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Gilteritinib. Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Gilteritinib. Salmeterol The risk or severity of adverse effects can be increased when Gilteritinib is combined with Salmeterol. Salmon calcitonin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Gilteritinib. Sapropterin The serum concentration of Gilteritinib can be increased when it is combined with Sapropterin. Saquinavir The metabolism of Gilteritinib can be decreased when combined with Saquinavir. Sarecycline The serum concentration of Gilteritinib can be increased when it is combined with Sarecycline. Sarilumab The metabolism of Gilteritinib can be increased when combined with Sarilumab. Satralizumab The serum concentration of Gilteritinib can be decreased when it is combined with Satralizumab. Secobarbital The metabolism of Gilteritinib can be increased when combined with Secobarbital. Secukinumab The metabolism of Gilteritinib can be increased when combined with Secukinumab. Selegiline The therapeutic efficacy of Selegiline can be decreased when used in combination with Gilteritinib. Selexipag The serum concentration of Gilteritinib can be increased when it is combined with Selexipag. Selumetinib Gilteritinib may decrease the excretion rate of Selumetinib which could result in a higher serum level. Sertindole The therapeutic efficacy of Sertindole can be decreased when used in combination with Gilteritinib. Sertraline The therapeutic efficacy of Sertraline can be decreased when used in combination with Gilteritinib. Sevoflurane The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Gilteritinib. Sibutramine The therapeutic efficacy of Sibutramine can be decreased when used in combination with Gilteritinib. Sildenafil The serum concentration of Gilteritinib can be increased when it is combined with Sildenafil. Silodosin The serum concentration of Gilteritinib can be increased when it is combined with Silodosin. Siltuximab The metabolism of Gilteritinib can be increased when combined with Siltuximab. Simeprevir The metabolism of Gilteritinib can be decreased when combined with Simeprevir. Simvastatin The serum concentration of Gilteritinib can be increased when it is combined with Simvastatin. Siponimod The metabolism of Siponimod can be decreased when combined with Gilteritinib. Sirolimus The metabolism of Sirolimus can be decreased when combined with Gilteritinib. Sitagliptin The serum concentration of Gilteritinib can be increased when it is combined with Sitagliptin. Sitaxentan The metabolism of Gilteritinib can be decreased when combined with Sitaxentan. Sofosbuvir Gilteritinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Gilteritinib. Solriamfetol The excretion of Solriamfetol can be decreased when combined with Gilteritinib. Somatostatin The metabolism of Gilteritinib can be decreased when combined with Somatostatin. Somatrogon The metabolism of Gilteritinib can be increased when combined with Somatrogon. Sonidegib The metabolism of Sonidegib can be decreased when combined with Gilteritinib. Sorafenib The metabolism of Sorafenib can be decreased when combined with Gilteritinib. Sotagliflozin The serum concentration of Gilteritinib can be increased when it is combined with Sotagliflozin. Sotalol The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Sotalol. Sotorasib The serum concentration of Gilteritinib can be decreased when it is combined with Sotorasib. Sparfloxacin The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Sparfloxacin. St. John's Wort The metabolism of Gilteritinib can be increased when combined with St. John's Wort. Stiripentol The metabolism of Gilteritinib can be decreased when combined with Stiripentol. Sulfamethoxazole The metabolism of Gilteritinib can be decreased when combined with Sulfamethoxazole. Sulfasalazine Gilteritinib may decrease the excretion rate of Sulfasalazine which could result in a higher serum level. Sulfinpyrazone The metabolism of Gilteritinib can be increased when combined with Sulfinpyrazone. Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Gilteritinib. Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Gilteritinib. Sultopride The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Sultopride. Sumatriptan The therapeutic efficacy of Sumatriptan can be decreased when used in combination with Gilteritinib. Sunitinib The metabolism of Sunitinib can be decreased when combined with Gilteritinib. Suvorexant The serum concentration of Gilteritinib can be increased when it is combined with Suvorexant. Tacrolimus The metabolism of Tacrolimus can be decreased when combined with Gilteritinib. Talazoparib Gilteritinib may decrease the excretion rate of Talazoparib which could result in a higher serum level. Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Gilteritinib. Tapentadol The therapeutic efficacy of Tapentadol can be decreased when used in combination with Gilteritinib. Tasimelteon The metabolism of Gilteritinib can be decreased when combined with Tasimelteon. Tazemetostat Gilteritinib may decrease the excretion rate of Tazemetostat which could result in a higher serum level. Technetium The serum concentration of Gilteritinib can be increased when it is combined with Technetium Tc-99m sestamibi. Tecovirimat The metabolism of Gilteritinib can be increased when combined with Tecovirimat. Tegaserod The therapeutic efficacy of Tegaserod can be decreased when used in combination with Gilteritinib. Telaprevir The metabolism of Gilteritinib can be decreased when combined with Telaprevir. Telavancin The risk or severity of QTc prolongation can be increased when Telavancin is combined with Gilteritinib. Telithromycin The metabolism of Gilteritinib can be decreased when combined with Telithromycin. Telotristat ethyl The serum concentration of Gilteritinib can be decreased when it is combined with Telotristat ethyl. Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Gilteritinib. Teniposide The metabolism of Teniposide can be decreased when combined with Gilteritinib. Tenofovir The serum concentration of Tenofovir alafenamide can be increased when it is combined with Gilteritinib. Tenofovir The serum concentration of Gilteritinib can be increased when it is combined with Tenofovir disoproxil. Tepotinib The serum concentration of Gilteritinib can be increased when it is combined with Tepotinib. Terbinafine The metabolism of Gilteritinib can be increased when combined with Terbinafine. Terbutaline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Gilteritinib. Terfenadine The metabolism of Gilteritinib can be decreased when combined with Terfenadine. Teriflunomide Gilteritinib may decrease the excretion rate of Teriflunomide which could result in a higher serum level. Teriparatide The therapeutic efficacy of Teriparatide can be decreased when used in combination with Gilteritinib. Terlipressin The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Gilteritinib. Testosterone Gilteritinib may decrease the excretion rate of Testosterone which could result in a higher serum level. Testosterone Gilteritinib may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. Testosterone Gilteritinib may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. Tetrabenazine The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Tetrabenazine. Tetracaine The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Tetracaine. Tetracycline The metabolism of Gilteritinib can be decreased when combined with Tetracycline. Tezacaftor The serum concentration of Gilteritinib can be increased when it is combined with Tezacaftor. Theophylline The metabolism of Theophylline can be decreased when combined with Gilteritinib. Thiamine The risk or severity of adverse effects can be increased when Gilteritinib is combined with Thiamine. Thiamylal The metabolism of Gilteritinib can be increased when combined with Thiamylal. Thioridazine The therapeutic efficacy of Thioridazine can be decreased when used in combination with Gilteritinib. Thiotepa The metabolism of Thiotepa can be decreased when combined with Gilteritinib. Thiothixene The therapeutic efficacy of Thiothixene can be decreased when used in combination with Gilteritinib. Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Gilteritinib. Thyrotropin alfa The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Gilteritinib. Ticagrelor The serum concentration of Gilteritinib can be increased when it is combined with Ticagrelor. Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Gilteritinib. Tipranavir The metabolism of Gilteritinib can be decreased when combined with Tipranavir. Tivozanib The serum concentration of Gilteritinib can be increased when it is combined with Tivozanib. Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Gilteritinib. Tocilizumab The metabolism of Gilteritinib can be increased when combined with Tocilizumab. Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Gilteritinib. Tolvaptan The metabolism of Tolvaptan can be decreased when combined with Gilteritinib. Topiramate The metabolism of Gilteritinib can be increased when combined with Topiramate. Topotecan The excretion of Topotecan can be decreased when combined with Gilteritinib. Toremifene The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Toremifene. Trabectedin The metabolism of Trabectedin can be decreased when combined with Gilteritinib. Tramadol The therapeutic efficacy of Tramadol can be decreased when used in combination with Gilteritinib. Tranylcypromine The therapeutic efficacy of Tranylcypromine can be decreased when used in combination with Gilteritinib. Trastuzumab The metabolism of Trastuzumab emtansine can be decreased when combined with Gilteritinib. Trazodone The therapeutic efficacy of Trazodone can be decreased when used in combination with Gilteritinib. Treprostinil The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Gilteritinib. Triamcinolone The metabolism of Gilteritinib can be increased when combined with Triamcinolone. Triclabendazole The metabolism of Gilteritinib can be decreased when combined with Triclabendazole. Triflupromazine The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Gilteritinib. Trilaciclib Gilteritinib may decrease the excretion rate of Trilaciclib which could result in a higher serum level. Trimebutine The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Gilteritinib. Trimethadione The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Gilteritinib. Trimipramine The therapeutic efficacy of Trimipramine can be decreased when used in combination with Gilteritinib. Triprolidine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Gilteritinib. Triptorelin The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Gilteritinib. Troglitazone The metabolism of Gilteritinib can be increased when combined with Troglitazone. Troleandomycin The metabolism of Gilteritinib can be decreased when combined with Troleandomycin. Tropisetron The therapeutic efficacy of Tropisetron can be decreased when used in combination with Gilteritinib. Trovafloxacin The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Trovafloxacin. Tubocurarine The risk or severity of adverse effects can be increased when Gilteritinib is combined with Tubocurarine. Tucatinib Tucatinib may decrease the excretion rate of Gilteritinib which could result in a higher serum level. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Gilteritinib. Umbralisib The serum concentration of Gilteritinib can be increased when it is combined with Umbralisib. Valproic acid The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Valproic acid. Vandetanib The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Vandetanib. Vardenafil The serum concentration of Gilteritinib can be increased when it is combined with Vardenafil. Velpatasvir Gilteritinib may decrease the excretion rate of Velpatasvir which could result in a higher serum level. Vemurafenib The serum concentration of Gilteritinib can be increased when it is combined with Vemurafenib. Venetoclax The metabolism of Venetoclax can be decreased when combined with Gilteritinib. Venlafaxine The therapeutic efficacy of Venlafaxine can be decreased when used in combination with Gilteritinib. Verapamil The metabolism of Gilteritinib can be decreased when combined with Verapamil. Vernakalant The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Gilteritinib. Vilanterol The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Gilteritinib. Vilazodone The therapeutic efficacy of Vilazodone can be decreased when used in combination with Gilteritinib. Viloxazine The metabolism of Gilteritinib can be decreased when combined with Viloxazine. Vinblastine The metabolism of Vinblastine can be decreased when combined with Gilteritinib. Vincristine The metabolism of Vincristine can be decreased when combined with Gilteritinib. Vindesine The metabolism of Vindesine can be decreased when combined with Gilteritinib. Vinflunine The metabolism of Vinflunine can be decreased when combined with Gilteritinib. Vinorelbine The metabolism of Vinorelbine can be decreased when combined with Gilteritinib. Vitamin E The metabolism of Gilteritinib can be increased when combined with Vitamin E. Voclosporin The serum concentration of Gilteritinib can be increased when it is combined with Voclosporin. Vorapaxar The serum concentration of Gilteritinib can be increased when it is combined with Vorapaxar. Voriconazole The serum concentration of Gilteritinib can be increased when it is combined with Voriconazole. Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Gilteritinib. Vortioxetine The therapeutic efficacy of Vortioxetine can be decreased when used in combination with Gilteritinib. Voxilaprevir Gilteritinib may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. Warfarin The metabolism of Warfarin can be decreased when combined with Gilteritinib. Yohimbine The therapeutic efficacy of Yohimbine can be decreased when used in combination with Gilteritinib. Zafirlukast The metabolism of Gilteritinib can be decreased when combined with Zafirlukast. Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Gilteritinib. Zidovudine Gilteritinib may decrease the excretion rate of Zidovudine which could result in a higher serum level. Zimelidine The therapeutic efficacy of Zimelidine can be decreased when used in combination with Gilteritinib. Ziprasidone The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Gilteritinib. Zolmitriptan The therapeutic efficacy of Zolmitriptan can be decreased when used in combination with Gilteritinib. Zonisamide The serum concentration of Gilteritinib can be increased when it is combined with Zonisamide. Zotepine The therapeutic efficacy of Zotepine can be decreased when used in combination with Gilteritinib. Zuclopenthixol The therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Gilteritinib. Drug-Food Interactions Avoid grapefruit products. Grapefruit inhibits CYP3A metabolism, which may increase the serum concentration of gilteritinib. Avoid St. John's Wort. This herb induces CYP3A4 and p-glycoprotein, which may reduce the serum concentration of gilteritinib. Take it at the same time every day. Take it with or without food. Pregnancy and Lactation US FDA pregnancy category Not Assigned Pregnancy This medication should not be used during pregnancy due to the risk that it may cause harm to the unborn baby. If you become pregnant while taking this medication, contact your doctor immediately. Lactation It is not known if gilteritinib passes into breast milk. If you are breast-feeding and are taking this medication, it may affect your baby. Women are advised to avoid breastfeeding while taking this medication and for 2 months after taking the last dose. How should this medicine be used?

Gilteritinib comes as a tablet to take by mouth. It is usually taken once daily with or without food for at least 6 months. Take gilteritinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take gilteritinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Swallow the…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)